Projects

At the beginning of 2021, we launched the ZIM partner project ADaPT-IT. In this project, we are working together with the Munich-based IT company Biomax Technology AG and the Institute for Immunology and Cell Biology at the University of Tübingen.

The aim of this project is to develop an AI-backed analysis platform for the highly precise identification of individual tumour epitopes (epitope=immunogenic tumour antigen) with the objective of developing highly effective, new individualised cancer therapies in precision medicine. One focus is on all forms of metastatic breast cancer. The project is funded by the German Ministry for Economic Affairs and Energy (BMWi) on the basis of a resolution of the German Bundestag.

 

A new year, a new challenge for the PMCR.

In 2022, we will officially launch the project: GENImmune, funded by the Federal Ministry of Education and Research (BMBF). In this project, we are working together with business enterprises, scientific institutions and university groups. GENImmune will provide an approach and software for using artificial intelligence (AI), machine learning (ML), natural language processing (NLP) and computational modelling (CM) to improve our understanding of host-pathogen interactions in infectious diseases and support clinically relevant applications such as vaccine development and drug target identification. Beyond the field of infectious diseases, the proposed method for mathematical representation of multicellular systems can also be applied to other diseases with strong immunological components, such as cancer and the interaction between tumour and immune system. An exemplary application is the optimisation of an existing development programme for variant-independent SARS-CoV-2 immunisation, which is not affected by antibody-dependent amplification